For Healthcare Professionals

A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease

clipboard-pencil

About the study

An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects with Fabry Disease and Amenable GLA Variants and Severe Renal Impairment (SRI) or End Stage Renal Disease (ESRD)
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Male or female subjects aged 18 years or older, diagnosed with Fabry disease.
  2. Subject (or legally authorized representative as applicable) is willing and able to provide written informed consent and authorization for use and disclosure of Personal Health Information
  3. Subject has a GLA variant that is amenable to migalastat recorded in their medical records
  4. Subject has at least 1 documented eGFR value of < 30 mL/min/1.73 m2 within the last 3 months and has an eGFRMDRD value of < 30 mL/min/1.73 m2 at Visit 1
  5. Subjects with ESRD have been on a stable 2- or 3-times a week HD (standard or HDF) regimen for at least 2 months prior to the screening visit
  6. Subjects with ESRD must commit to completing at least 4 standard HD or HDF sessions during each 2-week dosing interval.
  7. Subjects with ESRD must commit to completing the entire prescribed duration for each dialysis session.
  8. If of reproductive potential, both male and female patients agree to use a medically accepted method of contraception

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Subject has undergone kidney transplantation
  2. Subject is on peritoneal dialysis
  3. Subject is treated or has been treated with another investigational drug (except migalastat) within the 30 days
  4. Subject has undergone any gene therapy at any time prior to the study or anticipates undergoing gene therapy during the study.
  5. Subject has had a documented transient ischemic attack, stroke, unstable angina, or myocardial infarction
  6. Subject has clinically significant unstable cardiac disease
  7. Subject has any intercurrent illness or condition that may preclude the subject from fulfilling the protocol requirements
  8. Subject has a history of allergy or sensitivity to migalastat (including excipients) or other iminosugars (eg, miglustat, miglitol)
  9. Subject requires concurrent treatment with Glyset® (miglitol), Replagal® (agalsidase alfa), or Fabrazyme® (agalsidase beta)
  10. Subject requires concurrent treatment with Zavesca® (miglustat) or has been treated with Zavesca
  11. Female subject is pregnant or breast-feeding
  12. Subject is unable to comply with study requirements
  13. In France only, protected persons as defined by the Public Health Code

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Fabry Disease

Age (in years)

18+

Phase

Phase 3

Participants needed

14

Est. Completion Date

Dec 31, 2025

Treatment type

Interventional


Sponsor

Amicus Therapeutics

ClinicalTrials.gov identifier

NCT04020055

Study number

AT1001-025

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.